AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AbbVie Inc. on August 4, 2026. The filing discloses the execution of an underwriting agreement for a multi-tranche senior notes offering. The transaction is intended to support the company's acquisition of Apogee Therapeutics, Inc. and fund general corporate purposes.
Key Financial Metrics and Transaction Details
The company agreed to issue and sell a total of approximately $10.5 billion in aggregate principal amount of senior notes. The net proceeds from the sale, after deducting underwriting discounts and estimated offering expenses, are expected to be approximately $9.93 billion.
| Note Series | Principal Amount | Coupon Rate | Maturity |
|---|---|---|---|
| Floating Rate Notes | $500 million | Floating | 2028 |
| 2028 Notes | $1.0 billion | 4.500% | 2028 |
| 2030 Notes | $1.25 billion | 4.650% | 2030 |
| 2031 Notes | $1.5 billion | 4.875% | 2031 |
| 2033 Notes | $1.25 billion | 5.050% | 2033 |
| 2036 Notes | $1.5 billion | 5.300% | 2036 |
| 2038 Notes | $1.0 billion | 5.450% | 2038 |
| 2056 Notes | $1.5 billion | 6.000% | 2056 |
| 2066 Notes | $500 million | 6.100% | 2066 |
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Use of Proceeds
The primary material change is the increase in long-term debt obligations. The net proceeds of approximately $9.93 billion will be used to:
- Fund a portion of cash payment obligations for the acquisition of Apogee Therapeutics, Inc.
- Pay fees, expenses, and other amounts related to the acquisition.
- Reduce commitments under AbbVie's $10.0 billion 364-Day delayed draw term loan facility entered into for the Apogee acquisition.
- Service other general corporate purposes, which may include the repayment or repurchase of outstanding debt.
The closing of the sale is expected to occur on August 18, 2026, subject to customary closing conditions.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected closing date and the use of proceeds. These statements are subject to risks and uncertainties that could cause actual results to differ materially. The company refers investors to the "Risk Factors" and "Management's Discussion and Analysis" sections of its Annual Report on Form 10-K for the year ended December 31, 2025, for a detailed discussion of these risks. The company explicitly declines any obligation to update these forward-looking statements unless required by law.
Key Facts for Investor Verification
- Transaction Closing: Verify the final closing date (expected August 18, 2026) and the actual net proceeds received.
- Acquisition Status: Confirm the progress and final terms of the Apogee Therapeutics, Inc. acquisition.
- Debt Reduction: Monitor the specific amount of the $10.0 billion delayed draw term loan facility that is reduced by these proceeds.
- Interest Rate Exposure: Assess the impact of the floating rate notes and the fixed rates on future interest expense given the current market environment.
- Underwriting Fees: Review the final prospectus supplement for the exact underwriting discounts and offering expenses deducted from the gross proceeds.